tezosentan has been researched along with ranolazine in 1 studies
Studies (tezosentan) | Trials (tezosentan) | Recent Studies (post-2010) (tezosentan) | Studies (ranolazine) | Trials (ranolazine) | Recent Studies (post-2010) (ranolazine) |
---|---|---|---|---|---|
157 | 29 | 33 | 799 | 104 | 498 |
Protein | Taxonomy | tezosentan (IC50) | ranolazine (IC50) |
---|---|---|---|
Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 6.85 | |
Voltage-gated sodium channel Nav1.5 cardiac isoform | Canis lupus familiaris (dog) | 6.9 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dunlap, ME; Ibrahim, OA | 1 |
1 review(s) available for tezosentan and ranolazine
Article | Year |
---|---|
Combination pharmacologic therapies for heart failure: what next after angiotensin-converting enzyme inhibitors and beta-blockers?
Topics: Acetanilides; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Mineralocorticoid Receptor Antagonists; Piperazines; Pyridines; Ranolazine; Tetrazoles; Tolvaptan; Vasodilator Agents | 2005 |